Drug intelligence / Profile preview

Alaxan

Development stage
Unknown
Lead developer
United International Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Alaxan is an over-the-counter (OTC) fixed-dose combination analgesic developed and marketed by United International Pharma. It contains two active ingredients: Paracetamol (325 mg) and Ibuprofen (200 mg). Paracetamol acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system and elevating the pain threshold. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that provides anti-inflammatory, analgesic, and antipyretic effects by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the production of pro-inflammatory prostaglandins. Alaxan is primarily indicated for the management of mild to moderate musculoskeletal pain, including back pain, neck strain, sprains, and rheumatism, as well as headache, toothache, and menstrual pain.

Brand names
Alaxan
Other names
Paracetamol + IbuprofenIbuprofen and Paracetamol
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Alaxan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alaxan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call